Comprehensive analysis of relapsed-refractory mature B-cell non-Hodgkin lymphoma in children and adolescents.
Por:
Mato S, Carità L, Colmenero A, Andrés M, Balagué O, Andión M, Astigarraga I, Celis-Passini V, Mendoza C, Guerra-García P, Valero L, Galera A, Tallón M, Pol M, Castrejón-de-Anta N, Frauenfeld L, Garcia N, Campo E, Salaverria I and Verdú-Amorós J
Publicada:
1 may 2025
Ahead of Print:
26 feb 2025
Resumen:
The outcome of B-cell non-Hodgkin lymphoma (B-NHL) in children and adolescents has improved significantly over recent decades due to risk-adapted strategies and the use of immunotherapy. However, refractory or relapsed (R/R) B-NHL remains extremely difficult to cure (<30%). This retrospective study of 45 patients with R/R B-NHL reflects the limited benefit associated with reintroducing rituximab in second-line strategies, the importance of achieving complete remission before stem cell transplantation and the potential role of TP53 as a biomarker in R/R B-NHL. TP53 mutations were identified in 44% of tumours and associated with a worse 3-year overall survival (15% vs. 80%; p = 0.048).
Filiaciones:
Mato S:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Universitat de Barcelona, Barcelona, Spain
Carità L:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Colmenero A:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Universitat de Barcelona, Barcelona, Spain
Andrés M:
Paediatrics Haematology and Oncology Department, Hospital Universitario y Politécnico La Fe de Valencia, Valencia, Spain
Balagué O:
Hematopathology Section, Laboratory of Pathology, Hospital Clinic de Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
Andión M:
Paediatric Oncology Department, Hospital Universitario Infantil Niño Jesus, Madrid, Spain
Astigarraga I:
Department of Paediatrics, Hospital Universitario Cruces, Osakidetza, Bizkaia Health Research Institute, Bizkaia, Spain
UPV/EHU, Barakaldo, Spain
Celis-Passini V:
Paediatric Cancer Center Barcelona, Hospital Sant Joan de Déu, Barcelona, Spain
Mendoza C:
Paediatrics Hemato-Oncology Department, Complejo Asistencial Universitario de Salamanca, Salamanca, Spain
Guerra-García P:
Paediatric Haematology and Oncology Department, Hospital Universitario La Paz, Translational Research in Paediatric Oncology, Hematopoietic Transplantation and Cell Therapy, Instituto de Investigación Sanitaria del Hospital Universitario La Paz - IdiPAZ, Madrid, Spain
Valero L:
Paediatric Oncology and Hematology Department, Hospital Universitari Vall d'Hebron, Barcelona, Spain
Galera A:
Paediatric Oncohaematology Department, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain
Tallón M:
Haemato-Oncology Unit, Álvaro Cunqueiro Hospital, Vigo, Spain
Pol M:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Castrejón-de-Anta N:
Universitat de Barcelona, Barcelona, Spain
Hematopathology Section, Laboratory of Pathology, Hospital Clinic de Barcelona, Barcelona, Spain
Frauenfeld L:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Garcia N:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Campo E:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Universitat de Barcelona, Barcelona, Spain
Hematopathology Section, Laboratory of Pathology, Hospital Clinic de Barcelona, Barcelona, Spain
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
Salaverria I:
Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
Verdú-Amorós J:
Centro de Investigación Biomédica en Red de Cáncer (CIBERONC), Madrid, Spain
Department of Paediatric Haematology and Oncology, Hospital Clínico Universitario, Biomedical Research Institute, INCLIVA, Valencia, Spain
hybrid
|